|
EDUCATION
1982 Bachelor of Science
Auburn University Auburn, Alabama
Honors: Academic All-American - Baseball
ODK, Mortar Board
1986 Doctor of Medicine
University of Alabama Medical School
Birmingham, Alabama
1986-1988 General Surgery Internship
University of Alabama Medical Center
Birmingham, Alabama
1988-1992 Orthopaedic Surgery Residency
University of Alabama Medical Center
Birmingham, Alabama
|
PUBLICATIONS
Allografts in Trauma - submitted in December 1990 Southern Medical Journal
“A Double-Blind, Placebo-Controlled, Single-Dose Parallel study of the Analgesic Efficacy and safety of Oxycodone HCI 5MG/Ibuprofen 400MG and Oxycodone HCI 10MG/Ibuprofen 400MG Compared to Ibuprofen 400MG alone, Oxycodone HCI 5MG alone and Oxycodone HCI 10MG alone in Patients with Moderate to severe pain post-orthopedic Surgical pain’’ Forrest Laboratories, OXY-MD-07-000,2000
"A Randomized, Double-Blind, Multiple Dose Evaluation of the analgesic Efficacy and safety of Oxycodone HCI 5MG/Ibuprofen 400MG and Oxycodone HCI 10MG/Ibuprofen 400MG in Patients with Moderate to Severe Pain Following Dental or Orthopedic Surgery’’ Forrest Laboratories, OXY-MD-08-000,2000
“Multicenter, Randomized, Double-Blind, Placebo And Active Controls, Single Dose Study of Oxymophone Ir and Oxycodone Ir in Subjects With Pain Following Orthopedic Surgery” Endo Pharmaceuticals, Protocol No.: EN 3203-005,2001.
“A Phase III, Randoized, Multicenter, Parallel-group, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Diclofenac Potassium Softgel 25mg or 50 mg in the Treatment of Arthroscopic Knee Surgery Pain,” aaiPharma, Inc., Protocol No: AAL-000396,2001.
“A Randomized, Double-blind Evaluation of the Analgesic Efficacy and Safety of a Low Dose Oxymorphone Immediate Release in Patients Following Ambulatory Arthroscopic Knee Surgery.” EndoPharmaceuticals, EN3203-008,2003.
“Multi-center, double-blind, randomized, placebo-controlled, multiple dose study of the analgesic efficacy and safety of Acetaminophen injection 1g vs placebo for pain following primary total hip arthroplasty.” Bristol-Myers Squibb / ICON, Protocol No.: 136-02-03,2003.
|